ArticleJournal for immunotherapy of cancer2022

First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.

Omid Hamid et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.